Phenytoin infusion revisited: Stability and administration

Journal of Pharmacy Practice and Research

Volumn 34, Issue 4, 2004, Pages 272-275

  Milne, Dianne J ^a   Foo, Josephine ^b   Sharley, Nicholas A ^a   Milne, Robert W ^b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; POLYVINYLCHLORIDE; SODIUM CHLORIDE;

ABSORPTION SPECTROPHOTOMETRY; ARTICLE; DILUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INFUSION; DRUG MIXTURE; DRUG STABILITY; INJECTION; PARTICULATE MATTER; PH MEASUREMENT; ULTRAVIOLET SPECTROSCOPY;

EID: 13544266313     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jppr2004344272     Document Type: Article

References (20)

1. Winter ME, Tozer TN. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 2nd ed. Spokane: Applied Therapeutics Inc: 1986. p. 493.
2. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology 1978; 28: 874-80.
3. Earnest MP, Marx JA, Drury LR. Complications of intravenous phenytoin for acute treatment of seizures. JAMA 1983; 249: 762-5.
4. Carmichael RR, Mahoney CD, Jeffrey LP. Solubility and stability of phenytoin sodium when mixed with intravenous solutions. Am J Hosp Phann 1980; 37: 95-8.
5. Bauman JL, Siepler JK, Fitzloff J. Phenytoin crystallization in intravenous fluids. Drug Intell Clin Pharm 1977; 11: 646-9.
6. Pfeifele CE, Adler DS, Gannaway WL. Phenytoin sodium solubility in three intravenous solutions. Am J Hosp Pharm 1981; 38: 358-62.
7. Sistare F, Greene R. Phenytoin crystallization in intravenous fluids [letter]. Drug Intell Clin Pharm 1978; 12: 120.
8. Giacona N, Bauman JL, Siepler JK. Crystallization of three phenytoin preparations in intravenous solutions. Am J Hosp Pharm 1982; 39: 630-4.
9. Chan NL, Dilantin for IV use [letter]. Drug Intell Clin Pharm 1973; 7: 419.
10. Cloyd JC, Bosch DE, Sawchuk RJ. Concentration-time profile of phenytoin after admixing with small volumes of intravenous fluids. Am J Hosp Pharm 1978; 34: 45-8.
11. Frank JT. Dilantin for IV use. Author's response [letter]. Drug Intell Clin Pharm 1973; 7: 419.
12. Tobias DC, Kellick KA. Dilantin for IV use [letter]. Drug Intell Clin Pharm 1973; 7: 418.
13. Markowsky SJ, Kohls PR, Ehresman D, Leppik I. Compatability and pH variability of four injectable phenytoin sodium products. Am J Hosp Pharm 1991; 48: 510-14.
14. Salem RB, Yost RL, Torosian G, Davis FT, Wilder BJ. Investigations of the crystallization of phenytoin in normal saline. Drug Intell Clin Pharm 1980; 14: 605-8.
15. Agarwal SP, Blake MI. Determination of the pKa value for 5,5-diphenylhydantoin. J Pharm Sci 1968; 57: 1434-5.
16. Dill WA, Kazenko A, Wolf LM, Glazko AJ. Studies on 5,5-diphenylhydantoin (Dilantin) in animals and man. J Pharmacol Exp Ther 1956; 118: 270-9.
17. Schwartz PA, Rhodes CT, Cooper JW Jr. Solubility and ionization characteristics of phenytoin. J Pharm Sci 1977; 66: 994-5.
18. Newton DW, Kluza RB. Prediction of phenytoin solubility in intravenous admixtures: physicochemical theory. Am J Hosp Pharm 1980; 37: 1647-51.
19. Budavari S, editor. The Merck Index. 12th ed. Whitehouse Station: Merck & Co: 1996. p. 1260.
20. Koren JF, Taylor T. Phenytoin admixture solution: a review of the literature with recommendations. Hosp Pharm 1988; 23: 646-8.